Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
99.50
+0.11 (0.11%)
At close: Oct 6, 2025, 4:00 PM EDT
101.49
+1.99 (2.00%)
After-hours: Oct 6, 2025, 7:36 PM EDT
Monopar Therapeutics Employees
As of December 31, 2024, Monopar Therapeutics had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 6 or 60.00% compared to the previous year.
Employees
16
Change (1Y)
6
Growth (1Y)
60.00%
Revenue / Employee
n/a
Profits / Employee
-$1,081,774
Market Cap
716.84M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16 | 6 | 60.00% |
| Dec 31, 2023 | 10 | -2 | -16.67% |
| Dec 31, 2022 | 12 | 2 | 20.00% |
| Dec 31, 2021 | 10 | 0 | - |
| Dec 31, 2020 | 10 | 3 | 42.86% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MNPR News
- 12 days ago - Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 12 days ago - Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients - GlobeNewsWire
- 22 days ago - Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting - GlobeNewsWire
- 4 weeks ago - Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent - Seeking Alpha
- 4 weeks ago - Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting - GlobeNewsWire
- 7 weeks ago - Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments - GlobeNewsWire
- 4 months ago - Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers - GlobeNewsWire
- 4 months ago - Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - GlobeNewsWire